COVID-19 and Rates of Cancer Diagnosis in the US

被引:0
|
作者
Burus, Todd [1 ]
Lei, Feitong [1 ,2 ,3 ]
Huang, Bin [1 ,2 ,3 ]
Christian, W. Jay [4 ]
Hull, Pamela C. [1 ,5 ]
Ellis, Amanda R. [6 ]
Slavova, Svetla [6 ,7 ]
Tucker, Thomas C. [1 ,4 ]
Kuhs, Krystle A. Lang [1 ,4 ]
机构
[1] Univ Kentucky, Markey Canc Ctr, 760 Press Ave,Room 346, Lexington, KY 40508 USA
[2] Univ Kentucky, Coll Med, Div Canc Biostat, Lexington, KY USA
[3] Univ Kentucky, Markey Canc Ctr, Kentucky Canc Registry, Lexington, KY USA
[4] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol & Environm Hlth, Lexington, KY USA
[5] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY USA
[6] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY USA
[7] Univ Kentucky, Kentucky Injury Prevent & Res Ctr, Lexington, KY USA
关键词
CARE;
D O I
10.1001/jamanetworkopen.2024.32288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance US cancer diagnoses were substantially lower than expected during the COVID-19 pandemic in 2020. A national study on the extent to which rates recovered in 2021 has not yet been conducted. Objective To examine observed vs expected cancer rate trends for January 2020 to December 2021. Design, Setting, and Participants This cross-sectional, population-based study of cancer incidence trends used the Surveillance, Epidemiology, and End Results 22 (SEER-22) Registries Database, which covers 47.9% of the US population. Included individuals were those with an invasive cancer diagnosis reported to registries included in SEER-22 between January 1, 2000, and December 31, 2021. Exposures Age, sex, race and ethnicity, urbanicity, and stage at diagnosis. Main Outcomes and Measures Expected cancer incidence rates were measured for the COVID-19 pandemic years of 2020 and 2021 from prepandemic trends using ensemble forecasting methods. Relative difference between observed and expected cancer incidence rates and numbers of potentially missed cases were measured. Results The SEER-22 registries reported 1 578 697 cancer cases in 2020 and 2021, including 798 765 among male individuals (50.6%) and 909 654 among persons aged 65 years or older (57.6%). Observed all-sites cancer incidence rates were lower than expected by 9.4% in 2020 (95% prediction interval [PI], 8.5%-10.5%), lower than expected by 2.7% in 2021 (95% PI, 1.4%-3.9%), and lower than expected by 6.0% across both years combined (95% PI, 5.1%-7.1%), resulting in 149 577 potentially undiagnosed cancer cases (95% PI, 126 059-176 970). Of the 4 screening-detected cancers, only female breast cancer showed significant recovery in 2021, exceeding expected rates by 2.5% (95% PI, 0.1%-4.8%), while significant reductions remained for lung cancer (9.1% lower than expected; 95% PI, 6.4%-13.2%) and cervical cancer (4.5% lower than expected; 95% PI, 0.4%-8.0%), particularly for early stage at diagnosis. Rates of all-sites cancer incidence returned to prepandemic trends in 2021 among female individuals, persons aged younger than 65 years, and persons of non-Hispanic Asian and Pacific Islander race and ethnicity. Conclusions and Relevance This population-based cross-sectional study of US cancer incidence trends found that rates of diagnosis improved in 2021 but continued to be lower than expected, adding to the existing deficit of diagnosed cases from 2020. Particular attention should be directed at strategies to immediately increase cancer screenings to make up lost ground.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic
    Howlader, Nadia
    Bhattacharya, Manami
    Scoppa, Steve
    Miller, Daniel
    Noone, Anne-Michelle
    Negoita, Serban
    Cronin, Kathy
    Mariotto, Angela
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (02) : 208 - 215
  • [2] Changes in cancer incidence rates by stage during the COVID-19 pandemic in the US
    Schafer, Elizabeth J.
    Islami, Farhad
    Han, Xuesong
    Nogueira, Leticia M.
    Wagle, Nikita Sandeep
    Yabroff, K. Robin
    Sung, Hyuna
    Jemal, Ahmedin
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (05) : 786 - 792
  • [3] Stagnant US Mammography Rates and the Influence of COVID-19
    Suran, Melissa
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (18): : 1742 - 1744
  • [4] COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium
    Hong, J.
    Borno, H. T.
    Harismendy, O.
    Yousefi, S.
    Cinar, P.
    Rugo, H. S.
    Kim, M-O.
    Koshkin, V. S.
    Bailey, A.
    McKay, R. R.
    Small, E. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1135 - S1135
  • [5] Covid-19 is shattering US cancer care
    Nelson, Bryn
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [6] Modeling the change in European and US COVID-19 death rates
    Khan, Zeina S.
    Van Bussel, Frank
    Hussain, Fazle
    [J]. PLOS ONE, 2022, 17 (08):
  • [7] Rates of Routine Cancer Screening and Diagnosis Before vs After the COVID-19 Pandemic
    Oakes, Allison H.
    Boyce, Kelly
    Patton, Catherine
    Jain, Sanjula
    [J]. JAMA ONCOLOGY, 2023, 9 (01) : 145 - 146
  • [8] Cancer diagnosis in Brazil in the COVID-19 era
    Marques, Nelson Pereira
    Silveira, Denise Maria M.
    Marques, Nadia Carolina Teixeira
    Martelli, Daniella Reis Barbosa
    Oliveira, Eduardo A.
    Martelli-Junior, Hercilio
    [J]. SEMINARS IN ONCOLOGY, 2021, 48 (02) : 156 - 159
  • [9] COVID-19 and Us!
    El-Bawab, Tarek S.
    [J]. IEEE COMMUNICATIONS MAGAZINE, 2020, 58 (04) : 5 - 5
  • [10] Cancer diagnosis and treatment in the COVID-19 era
    Weller, David
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2020, 29 (03)